AcelRx Pharmaceuticals traded at $2.08 this Friday February 3rd, decreasing $0.12 or 5.45 percent since the previous trading session. Looking back, over the last four weeks, AcelRx Pharmaceuticals lost 3.26 percent. Over the last 12 months, its price rose by 379.93 percent. Looking ahead, we forecast AcelRx Pharmaceuticals to be priced at 1.92 by the end of this quarter and at 1.74 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
AcelRx Pharmaceuticals 2.08 -0.12 -5.45% 379.93%
Acura Pharmaceuticals 0.05 0 0% -89.53%
Baxter International 46.68 -0.33 -0.70% -46.17%
Becton, Dickinson and Co. 245.84 -2.63 -1.06% -8.56%
Cara Therapeutics 12.26 0.31 2.59% 15.01%
Heron Therapeutics 2.84 -0.06 -2.07% -66.74%
Intra Cellular Therapies 48.92 -0.82 -1.65% 0.41%
J&J 164.61 -0.93 -0.56% -4.09%
Pfizer 44.06 -0.28 -0.63% -16.87%
Cassava Sciences Inc. 30.92 -0.60 -1.90% -35.33%
Smiths 1,795.00 11.50 0.64% 16.33%
Teva Pharmaceutical Industries Ltd 3,605.00 -6.00 -0.17% 32.88%
Xeris Pharmaceuticals Inc 1.18 -0.08 -6.35% -45.12%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%
US2000 1986 -15.69 -0.78% -0.84%

AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s product candidates DSUVIA, known as DZUVEO in Europe and Zalviso are both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. DSUVIA is indicates for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers and emergency departments for the management of acute pain severe enough to require an opioid analgesic. Zalviso is designed to help address certain problems associated with post-operative IV patient-controlled analgesia (PCA). Zalviso allows patients to self-administer sufentanil sublingual tablets via a pre-programmed, secure system designed in part to eliminate the risk of healthcare provider programming errors.